191 related articles for article (PubMed ID: 32812835)
1. Assessment of the role of afucosylated glycoforms on the
Kwiatkowski A; Co C; Kameoka S; Zhang A; Coughlin J; Cameron T; Chiao E; Bergelson S; Schmid Mason C
MAbs; 2020; 12(1):1803645. PubMed ID: 32812835
[TBL] [Abstract][Full Text] [Related]
2. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
3. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.
Chung S; Quarmby V; Gao X; Ying Y; Lin L; Reed C; Fong C; Lau W; Qiu ZJ; Shen A; Vanderlaan M; Song A
MAbs; 2012; 4(3):326-40. PubMed ID: 22531441
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms.
Cambay F; Forest-Nault C; Dumoulin L; Seguin A; Henry O; Durocher Y; De Crescenzo G
Mol Immunol; 2020 May; 121():144-158. PubMed ID: 32222585
[TBL] [Abstract][Full Text] [Related]
6. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
7. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.
Yu M; Brown D; Reed C; Chung S; Lutman J; Stefanich E; Wong A; Stephan JP; Bayer R
MAbs; 2012; 4(4):475-87. PubMed ID: 22699308
[TBL] [Abstract][Full Text] [Related]
8. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function.
Popp O; Moser S; Zielonka J; Rüger P; Hansen S; Plöttner O
MAbs; 2018; 10(2):290-303. PubMed ID: 29173063
[TBL] [Abstract][Full Text] [Related]
9. Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
Hatfield G; Tepliakova L; Gingras G; Stalker A; Li X; Aubin Y; Tam RY
Front Immunol; 2022; 13():972168. PubMed ID: 36304448
[TBL] [Abstract][Full Text] [Related]
10. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
[TBL] [Abstract][Full Text] [Related]
11. Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity.
Sun Y; Izadi S; Callahan M; Deperalta G; Wecksler AT
J Biol Chem; 2021 Jul; 297(1):100826. PubMed ID: 34044019
[TBL] [Abstract][Full Text] [Related]
12. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
13. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.
Chung AW; Crispin M; Pritchard L; Robinson H; Gorny MK; Yu X; Bailey-Kellogg C; Ackerman ME; Scanlan C; Zolla-Pazner S; Alter G
AIDS; 2014 Nov; 28(17):2523-30. PubMed ID: 25160934
[TBL] [Abstract][Full Text] [Related]
14. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
[TBL] [Abstract][Full Text] [Related]
15. Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies.
Kuhns S; Shu J; Xiang C; Guzman R; Zhang Q; Bretzlaff W; Miscalichi N; Kalenian K; Joubert M
J Biotechnol; 2020 Jun; 317():5-15. PubMed ID: 32361021
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.
Pace D; Lewis N; Wu T; Gillespie R; Leiske D; Velayudhan J; Rohrbach A; Connell-Crowley L
Biotechnol Prog; 2016 Sep; 32(5):1181-1192. PubMed ID: 27160519
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
18. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
[TBL] [Abstract][Full Text] [Related]
19. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
[TBL] [Abstract][Full Text] [Related]
20. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
